Today: September 24, 2017, 1:50 am
  
Health

Dengue Vaccines Market - Global Industry Insights and Forecast 2016-2024

DENGUE VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024
Dengue Vaccines Market
Dengue Vaccines Market
PR-Inside.com: 2017-09-14 12:23:28
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has since spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths among children and adults in these regions.


Request a sample pdf Copy of report @ www.coherentmarketinsights.com/insight/request-sample/23

Prevalent Scenario in the Global Dengue Vaccines Market

Member states in three of the WHO regions regularly report the annual number of dengue cases. These statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO) mentions that there are around 390 million dengue cases worldwide each year, with number of cases reported increasing each year. In 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths. Dengue is a pertinent health issue affecting people across South America, Europe, and Asia. A large number of dengue outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000 suspected cases of dengue in Malaysia. This was a staggering 59.5% and 16% increase respectively in the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers lucrative growth opportunities for vaccine manufacturers.

Dengvaxia – the only approved product in the global dengue vaccines market

Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.

India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.

Get discount on this report @ www.coherentmarketinsights.com/insight/request-discount/23

Dengue Vaccines Market Outlook – Research Pipeline

There are approximately five vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.

Press Information
Coherent Market Insights
1001 4th Ave, #3200

Mr. Shah
CEO
2067016702
email
www.coherentmarketinsights.com/ongoing-insight/dengue-vaccines-m ..


# 591 Words
Related Articles
More From The Author
Biopharmaceuticals and Biomedicine Market – Global Industry [..]
Biopharmaceuticals and Biomedicine Market Introduction Biopharmaceuticals has emerged as one of the key segments holding immense [..]
Artificial Retina Market - Global Industry Insights [..]
Artificial retina market is a major breakthrough in medical devices industry, wherein many universities and leading medical devices [..]
Small Animal Imaging Market — Global Industry [..]
Small animal imaging is a technique employed using devices and reagents for imaging biological processes in animals such as [..]
Air Ambulance Services Market - Global Industry [..]
Advancements in healthcare technology along with increasing patient inclination towards faster and efficient mode of delivery has [..]
Medical Electrodes Market Value Share, Analysis and [..]
According to The World Health Organization’s estimates in 2012, the global geriatric population was pegged at 901 million in [..]
 
More From Health
FSIVF Announces Free Consultation for the Patients [..]
FSIVF has announced the facility of free consultation for the first time for the patients up to 31st October in [..]
Achieving Low Cholesterol Levels Now Possible With [..]
According to a new study, nearly nine in ten patients with high LDL cholesterol levels could improve their condition with [..]
Alternative Weight Loss Method Has Been Developed [..]
Garcinia mangostana, also known as purple mangosteen is a tropical evergreen tree believed to have originated in the Sunda Islands [..]
Invacare launch revolutionary powerchair app
In an increasingly connected world a technological gap had begun to develop between disability aids and users. Everything from [..]
Invacare introduce next generation programming to powerchairs
Global brand leader Invacare has revolutionised how powerchairs are programmed – thanks to its LiNX technology. The LiNX control [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.